Table 2. Patient profile according to TRPM7 expression in basal subtype breast cancer patients.
| Basal subtype | TRPM7 high/low | Oncogenic kinases aspotential siRNA targetgenes (%: proportion ofhighly expressed cases) |
| 49 cases | 12 cases with highTRPM7 expression | EGFR: 75.00% cases |
| CDK6: 83.33% cases | ||
| MET: 75.00% cases | ||
| PIM1: 75.00% cases | ||
| ABL2: 41.67% cases | ||
| 37 cases with lowTRPM7 expression | EGFR: 91.89% cases | |
| CDK6: 54.05% cases | ||
| MET: 54.05% cases | ||
| PIM1: 43.24% cases | ||
| ABL2: 62.16% cases |
We observed TRPM7, Mg2+ ion importing protein-coding gene, was differentially expressed even in the same cancer subtype. It indicates that Mg2+ ion concentration is different from individual to individual and subsequently siRNA efficacy for potential oncogeneic kinases could differ. We set “Select Cancer Study”, “Select Genomic Profiles”, “Enter a z-score threshold”, and “Select Patient/Case Set” to “Breast Invasive Carcinoma (TCGA, Nature 2012)”, “mRNA Expression z-Scores (microarray)”, 1.0, and “PAM50 Basal”, respectively, in cBioportal.org. The z-score threshold is used to identify high or low-regulated genes. According to high or low TRPM7 expression, the patients were divided to 12 high TRPM7-expressed cases and 37 low TRPM7-expressed cases (total 49 patients). The efficacy of siRNA for the target genes could be lower in the patients with high TRPM7 expression, whereas the RNAi therapeutic intervention for the target genes could be more favorable for the patients with low TRPM7 expression. For example, siRNAs targeting EGFR would be preferable for 91.89% of the TRPM7 down-regulated patients, while the siRNAs would not be preferable for the majority (75%) of TRPM7 up-regulated patients. More comprehensive data for other oncogenic kinases are in Tables S4–S37 in File S1.